Asian Tech Press (Nov 17) -- Novavax and SK bioscience, a Korean biotechnology company, announced the submission of a Biologics License Application (BLA) for Novavax's Coronavirus vaccine to the Korean Ministry of Food and Drug Safety (MFD).

NVX-CoV2373, Novavax's recombinant nanoparticle Coronavirus vaccine (with Matrix-M™ adjuvant), is its first protein-based Coronavirus vaccine submitted to the BLA in South Korea.

It is worth noticing that, Novavax recently announced the licensing of its vaccine in Indonesia.